Lung Cancer ALK Rearrangement May Predict Pemetrexed Efficacy, Study Shows
Links shared publicly online about this topic.
- 21total visits
Lung Cancer ALK Rearrangement May Predict Pemetrexed Efficacy, Study Shows
View full resource at medicalnewstoday.com
Tags: Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Medication, Lung, Alimta
Most Recently Shared on September 5, 2011 at 7:05 am By:
Lung Cancer ALK Rearrangement May Predict Pemetrexed Efficacy, Study Shows http://mnt.to/3Zpc #lungcancer
Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows
eurekalert.org — “Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).” View full resource at eurekalert.org
Most Recently Shared on September 2, 2011 at 7:20 pm By:
Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows: (International Association for the S... http://t.co/u0Iyjbt
Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows
eurekalert.org — “Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).” View full resource at eurekalert.org
Most Recently Shared on September 1, 2011 at 7:06 pm By:
Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows: ( International Association for the ... http://t.co/igBmUh1
Advertisement
